Furthermore, TNFAIP3 and NFKBIA mutations, which activate the NF-κB pathway, are detected mostly in EBV-negative CHLs, indicating that LMP1 plays a vital role in activating NF-κB in EBV-positive CHL [57,118]. This evidence concerns the gene NFKB1 and Aagenaes syndrome.